scholarly journals Pubic Osteomyelitis after Treatment for Prostate Cancer A Case Report and Review of the Literature

2018 ◽  
Vol 2 (3) ◽  
pp. 1-4
Author(s):  
Els Van Nieuwenhuyse

Osteomyelitis pubis is a known, rare complication related with the treatment of prostate cancer. It can occur after surgery, radiotherapy and after ultrasound therapy. The latency between the treatment modality and the onset of the osteomyelitis is different for all treatment options. Symptoms are mostly subtle and non - specific, causing a delay in the diagnosis. For the diagnostic work - up, clinical examination, laboratory tests and medical imaging are necessary. The irrevocable diagnosis will be made by culture of a bone aspirate. Treatments consist of antibiotic therapy and surgery. The medical condition of the patient and the location of the infection determine the type and extent of the surgical modality.

2017 ◽  
Vol 11 (3) ◽  
pp. 331
Author(s):  
Andrea D'Amato ◽  
Costantino Mancusi ◽  
Maria Viviana Carlino ◽  
Veronica Lio ◽  
Federica De Pisapia ◽  
...  

We present the case of a 59-year-old patient with severe aortic stenosis, asymptomatic mild to moderate pericardial effusion and no major risk factors for poor prognosis. He underwent four-week course of non-steroidal anti-inflammatory drugs (ibuprofen 600 mg TID) with no improvement of the effusion. After complete diagnostic work-up and examination, we discovered that he had a prostate cancer with bone metastasis. On the bone scintigraphy, there was particular involvement of ribs and sternum. We decided to treat our patient with an association of docetaxel and hormone therapy, after six months we observed a reduction in the pericardial effusion. Even in the presence of a patient without risk factor of poor prognosis, pericardial effusion can be the first sign of occult neoplasia.


2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 5061-5061
Author(s):  
Anne Sofie Friberg ◽  
Klaus Brasso ◽  
Elisabeth Wreford Andersen ◽  
Signe Benzon Larsen ◽  
John Thomas Helgstrand ◽  
...  

5061 Background: Little is known about the psychological impact of undergoing evaluation for prostate cancer (PCa). We investigated the risk of developing a depression following PCa work-up with benign and malignant findings, respectively, compared with cancer-free men. Methods: A nationwide cohort of men who underwent prostate needle biopsies in Denmark from 1997–2011 was identified through the Danish Prostate Cancer Registry. Primary outcome was indication of moderate to severe depression defined as hospital contact for depression or first redemption of a prescribed antidepressant. For comparison, we selected a minimum of five age-matched cancer-free men per man who had undergone PCa specific diagnostic work-up. We excluded men with other cancer, major psychiatric disorder or use of antidepressants up to three years before study entry. Information on outcome and covariates (age, period, cohabitation status, income quintile and comorbidity) were retrieved from National Danish registries. We illustrated the risk of depression by cumulative incidence functions. Data were analyzed using Cox models adjusted for possible confounders. Results: We identified 54,766 men who underwent work-up including transrectal biopsies of the prostate, among these, 21,419 biopsy sets were benign and 33,347 men were diagnosed with PCa. We found an increasing cumulative incidence of depression in all groups. However, men diagnosed with PCa had a significantly higher risk throughout up to 18 years of follow-up. The adjusted hazard ratio (HR) of depression in men diagnosed with PCa was increased throughout follow-up with the highest risk in the two years following diagnosis (HR 2.77, 95% CI 2.66–2.87). After undergoing biopsies, men with benign results had an increased risk of depression (HR 1.22, 95% CI 1.14–1.31) in the first two years compared with cancer-free men; hereafter, we found no difference. Conclusions: We found an increased risk of depression in men following diagnostic work-up for PCa compared with a matched background population. In men diagnosed with PCa, the risk remained increased throughout the study period. Future studies are needed to further analyze the impact of stage and treatment modalities.


ESC CardioMed ◽  
2018 ◽  
pp. 1911-1917 ◽  
Author(s):  
Adriaan A. Voors ◽  
Piotr Ponikowski

Acute heart failure is a life-threatening medical condition typically leading to urgent hospital admission. Early diagnosis is of great importance, since it will lead to earlier and better targeted treatment, leading to a decrease in length of hospital stay, and most importantly to improved clinical outcome. The initial diagnostic work-up includes a clinical history, evaluation of symptoms and signs, an electrocardiogram, chest X-ray, natriuretic peptide levels, echocardiography and perhaps lung ultrasound. After the initial work-up, a clinical classification according to blood pressure, congestion, and peripheral perfusion should be performed, since it will guide treatment. During the diagnostic work-up, treatable and life-threatening conditions always need to be considered since they need immediate and case-specific treatment.


Author(s):  
Niek F. Casteleijn ◽  
Jeroen Veltman ◽  
Sicco J. Braak ◽  
Erik B. Cornel

2012 ◽  
Vol 3 ◽  
Author(s):  
A. W. G. Buijink ◽  
M. F. Contarino ◽  
J. H. T. M. Koelman ◽  
J. D. Speelman ◽  
A. F. van Rootselaar

Open Medicine ◽  
2009 ◽  
Vol 4 (3) ◽  
pp. 363-368
Author(s):  
Maria Scalzone ◽  
Paola Coccia ◽  
Palma Maurizi ◽  
Giorgio Attinà ◽  
Lucia Liotti ◽  
...  

AbstractChildhood aplastic anaemia (AA) is an uncommon but potentially fatal haematological disorder. Patients with AA receive supportive care based on transfusions and timely treatment of opportunistic infections, along with specific therapies, which may be bone marrow transplantation and immunosuppressive therapy. Early diagnosis and supportive therapy are required to prevent fatal complications like overwhelming sepsis or life threatening haemorrhages. We report two cases of aplastic anaemia having a different aetiology. The diagnostic work-up and the therapeutic management for each case are described below.


2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Constantine N. Logothetis ◽  
Joel Fernandez ◽  
Damian A. Laber

Amyloidosis is an underappreciated medical condition with symptoms camouflaging as common medical comorbidities leading to its underdiagnosis due to its systemic involvement. Despite common misconceptions, amyloidosis and its systemic comorbidities are more prevalent and treatable than previously acknowledged by the medical community. There are two major forms of amyloidosis: amyloid light-chain and transthyretin amyloidosis. Each of these have a distinct pathophysiology, diagnostic work-up, treatment, and prognosis. The patient described in this study was diagnosed with transthyretin cardiac amyloidosis months after presenting with heart failure of unknown etiology. Usually, clinicians presume that heart failure results from common comorbidities such as hypertension, diabetes, and hyperlipidemia. Here, the correct etiology was transthyretin cardiac amyloidosis. The patient had five admissions for heart failure symptoms prior to a physician identifying the etiology as cardiac transthyretin amyloidosis. After initiating the transthyretin stabilizer tafamidis, the patient did not experience another heart failure exacerbation. This vignette provides an example of the clinical presentation, diagnostic work-up, and treatment of a patient with cardiac transthyretin amyloidosis. The review of the literature focuses on the epidemiology, and clinical symptoms that should prompt an evaluation for cardiac amyloidosis as well as the diagnostic and therapeutic options are available. Transthyretin cardiac amyloidosis is a rare and underdiagnosed disease, while heart failure is a highly prevalent condition. This clinical vignette seeks to provide education and awareness to an overlooked medical disorder.


2018 ◽  
Vol 32 ◽  
pp. 205873841880641 ◽  
Author(s):  
Sara Torretta ◽  
Michele Gaffuri ◽  
Tullio Ibba ◽  
Pasquale Capaccio ◽  
Paola Marchisio ◽  
...  

Non-tuberculous mycobacterial lymphadenitis (NTML) accounts for about 95% of the cases of head-and-neck mycobacterial lymphadenitis, and its prevalence has been increasing in the Western world. The diagnostic work-up can be challenging, and differential diagnoses such as tuberculous and suppurative lymphadenitis need to be considered. It may, therefore, not be diagnosed until the disease is in a late stage, by which time it becomes locally destructive and is characterized by a chronically discharging sinus. The treatment options include a medical approach, a wait-and-see policy, and surgery, with the last being considered the treatment of choice despite the high risk of iatrogenic nerve lesions. The aim of this article is to provide an overview of pediatric, head-and-neck NTML based on the literature and our own experience, with particular emphasis on the impact and limitations of surgery.


Sign in / Sign up

Export Citation Format

Share Document